{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:14:40Z","timestamp":1789719280192,"version":"4.0.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5529","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T22:05:35Z","timestamp":1463263535000},"page":"1341-1344","source":"Crossref","is-referenced-by-count":25,"title":["Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib"],"prefix":"10.2169","volume":"55","author":[{"given":"Keita","family":"Kirito","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121: 4832-4837, 2013.","DOI":"10.1182\/blood-2013-02-482232"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Research Notes 5: 552, 2012.","DOI":"10.1186\/1756-0500-5-552"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wysham NG, Sullivan DR, Allada G. AN opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. CHEST Journal 143: 1478-1479, 2013.","DOI":"10.1378\/chest.12-1604"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 369: 681-683, 2013.","DOI":"10.1056\/NEJMc1302895"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28: 225-227, 2014.","DOI":"10.1038\/leu.2013.235"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shen CH, Hwang CE, Chen YY, Chen CC. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93: 1075-1076, 2014.","DOI":"10.1007\/s00277-013-1936-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426-435, 2015.","DOI":"10.1056\/NEJMoa1409002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43: 209-220, 2006.","DOI":"10.1002\/hep.21051"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ikeda M. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol 43: 8-16, 2013.","DOI":"10.1093\/jjco\/hys191"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368: 161-170, 2013.","DOI":"10.1056\/NEJMra1202117"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Heine A, Held SAE, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function <i>in vitro<\/i> and <i>in vivo<\/i>. Blood 122: 1192-1202, 2013.","DOI":"10.1182\/blood-2013-03-484642"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2: 43-50, 2002.","DOI":"10.1016\/S1473-3099(01)00172-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799-807, 2012.","DOI":"10.1056\/NEJMoa1110557"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.","DOI":"10.1056\/NEJMoa1110556"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and\/or autologous stem cell transplantation for cancer. J Viral Hepat 17: 807-815, 2010.","DOI":"10.1111\/j.1365-2893.2009.01239.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing profile, and precore\/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol 42: 241-249, 2007.","DOI":"10.1007\/s00535-006-1997-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212-2219, 2012.","DOI":"10.1016\/j.vaccine.2011.12.116"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 46: 9-16, 2011.","DOI":"10.1007\/s00535-010-0331-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122: 3843-3844, 2013.","DOI":"10.1182\/blood-2013-10-531103"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/10\/55_55.5529\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:42:11Z","timestamp":1498311731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/10\/55_55.5529\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5529","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}